

D-1 | What's New in GBCC 2026

By GBCC Scientific Program Committee

Eun Young Kim (Kangbuk Samsung Hospital)

Sae Byul Lee (Univ. of Ulsan College of Medicine)

A Full 3-Day Program for a More Comprehensive Scientific Experience

GBCC 2026 now offers a full 3-day scientific program, offering a more comprehensive and structured academic experience. Attendees will benefit from increased session availability, improved scheduling balance, and enhanced opportunities for networking and collaboration.

An Enhanced Plenary Program with Six Plenary Lectures for Broader Scope and Greater Impact

The number of Plenary Lectures has increased from five to six, featuring world-leading experts across all disciplines reflecting GBCC's continued evolution as a global academic platform.

This year's plenary sessions comprehensively cover key domains in breast cancer, from surgery and radiation to systemic therapy and tumor biology.

These include modern axillary surgery in node-positive breast cancer, addressing the shift from extensive surgery toward tailored approaches that balance staging needs with long-term morbidity; tumor evolution and precision oncology, highlighting treatment resistance, tumor microenvironment dynamics, and future directions including AI and liquid biopsy; and next-generation antibody–drug conjugates (ADCs), focusing on innovative drug design strategies to overcome resistance, tumor heterogeneity, and toxicity limitations.

Additional topics include advanced radiation therapy strategies, presenting phase III evidence supporting hypo fractionated locoregional radiotherapy in high-risk breast cancer patients, as well as de-escalation and personalized treatment strategies, emphasizing how treatment intensity can be safely reduced based on tumor biology and

patient selection, and advancing endocrine-based therapy, addressing optimization of endocrine treatment and overcoming resistance in HR-positive disease.

Together, these six plenary sessions provide a comprehensive overview of current practice-changing advances and future directions in breast cancer management.

The addition of a sixth plenary lecture allows for broader thematic coverage, better balance across disciplines, and inclusion of emerging scientific areas.

A New “General Session” Highlighting Practice-Changing Research

A newly introduced General Session will showcase the top-ranked abstracts across all submissions, regardless of initial category selection. This session is designed to present high-impact, clinically meaningful studies and elevate the scientific standard of GBCC.

The GBCC Best Academic Award Recognizing Excellence in Research

GBCC 2026 launches the GBCC Best Academic Award, with a \$10,000 prize awarded to the top presentation in the General Session. This initiative aims to highlight research with the greatest clinical impact and to promote high-quality global scientific contributions.

Award-winning study will be published in the Journal of Breast Cancer, the Official Journal of Korean Breast Cancer Society.

Enhanced Multidisciplinary Sessions for Broader Scope and Deeper Insights

New and expanded sessions include multidisciplinary sessions (AI, liquid biopsy, BRCA, young breast cancer), consensus session for global clinical perspectives, and integrated joint sessions with international societies. These sessions aim to strengthen global collaboration and real-world clinical application.

Introducing New Presentation Formats for More Interactive and Diverse Participation

These include Mini Oral Sessions for high-quality abstracts, Poster Discussion Sessions for interactive learning, and improved session structure for better engagement. These formats are designed to enhance audience participation and discussion.

Expanded Global Participation for Stronger International Collaboration

GBCC 2026 continues to grow as a global platform, featuring participation from 50+ countries, increased collaboration with international societies, and dedicated programs for young investigators and global networking.

Looking Ahead

With an expanded program, strengthened plenary content, and new academic initiatives, GBCC 2026 continues to evolve as a leading international conference in breast cancer research.

“Go Beyond Cure of Breast Cancer,” GBCC 2026 will bring together innovation, collaboration, and clinical excellence on a global stage.